950 related articles for article (PubMed ID: 15966198)
1. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
3. [Significance of subtype pattern of antimitochondrial antibodies in primary biliary cirrhosis for prognostic parameters and response to ursodeoxycholic acid].
Wirth HP; Zala G; Meyenberger C; Ammann R
Schweiz Med Wochenschr; 1995 Apr; 125(15):750-4. PubMed ID: 7740290
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
5. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
Babatin MA; Sanai FM; Swain MG
Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
[TBL] [Abstract][Full Text] [Related]
7. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
Heathcote EJ; Cauch-Dudek K; Walker V; Bailey RJ; Blendis LM; Ghent CN; Michieletti P; Minuk GY; Pappas SC; Scully LJ
Hepatology; 1994 May; 19(5):1149-56. PubMed ID: 8175136
[TBL] [Abstract][Full Text] [Related]
8. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK
Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295
[TBL] [Abstract][Full Text] [Related]
9. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
10. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
Batts KP; Jorgensen RA; Dickson ER; Lindor KD
Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
[TBL] [Abstract][Full Text] [Related]
11. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
[TBL] [Abstract][Full Text] [Related]
12. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
Olsson R
Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
[TBL] [Abstract][Full Text] [Related]
13. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis.
Jorgensen R; Angulo P; Dickson ER; Lindor KD
Am J Gastroenterol; 2002 Oct; 97(10):2647-50. PubMed ID: 12385454
[TBL] [Abstract][Full Text] [Related]
14. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
15. [Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood--clinical and biochemical effects].
Kardorff R; Melter M; Rodeck B; Brodehl J
Klin Padiatr; 1996; 208(3):118-22. PubMed ID: 8676599
[TBL] [Abstract][Full Text] [Related]
16. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis.
Kuiper EM; Hansen BE; Lesterhuis W; Robijn RJ; Thijs JC; Engels LG; Koek GH; Aparicio MN; Kerbert-Dreteler MJ; van Buuren HR;
Clin Res Hepatol Gastroenterol; 2011 Jan; 35(1):29-33. PubMed ID: 20810227
[TBL] [Abstract][Full Text] [Related]
17. [Drug therapy of cholestatic hepatopathies].
Leuschner U
Schweiz Rundsch Med Prax; 1992 Aug; 81(34):983-4. PubMed ID: 1529191
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
Lee YM; Kaplan MM
Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
[TBL] [Abstract][Full Text] [Related]
19. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ
Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416
[TBL] [Abstract][Full Text] [Related]
20. [Primary biliary cirrhosis: therapeutic options].
Abenavoli L
Recenti Prog Med; 2009 Sep; 100(9):417-23. PubMed ID: 19886235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
